SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Billions is the global human and AI network, built on mobile-first verification to scale the internet of value. We uniquely verify the identity and uniqueness of humans and AI agents, empowering users with personalized experiences and rewards.  ‍Our network is designed to be accessible, scalable, and anonymous, making trust between humans and AI seamless and intuitive for everyone.

TillBilly

TillBilly is seeing significant volatility as community members debate its potential for explosive growth against concerns regarding circulating supply and potential market manipulation. The project is drawing comparisons to other high-momentum tokens, with traders closely monitoring its price action and liquidity levels amidst intense social media speculation.

Volvo AB engages in the design, manufacture, and market of commercial vehicles. It operates through the following segments: Trucks, Construction Equipment, Buses, Volvo Penta, and Financial Services. The Trucks segment includes the production, development, and logistics for powertrain and parts. The Volvo Penta segment markets marine and industrial engines. The company was founded by Assar-Thorvald Nathanael-Gabrielsson and Erik Gustaf Larson in 1927 and is headquartered in Goteborg, Sweden.

Volvo AB - ADR - Unsponsored

VOLVO AB/ADR

Volvo is currently trending following an expanded partnership with BlackBerry to integrate software-defined audio solutions into its upcoming EX60 electric SUV. This move to modernize vehicle architecture, combined with ongoing community discussions regarding the company's autonomous trucking strategy and its transition toward an all-electric lineup, continues to drive investor interest.

Ethereum is a global, open-source platform for decentralized applications. In other words, it is a decentralized blockchain platform that enables developers to build and deploy smart contracts and applications without central authority control. Unlike Bitcoin, which primarily functions as digital currency, Ethereum operates as a programmable global computer where developers can create any type of decentralized service.   The platform hosts over $14 billion in DeFi applications with hundreds of thousands of active users across financial protocols, NFT marketplaces, and gaming platforms. Its transition to Proof of Stake in September 2022 reduced energy consumption by over 99%, addressing environmental concerns while strengthening network security.  The network operates through thousands of independent validator nodes that process transactions and execute smart contracts on the Ethereum Virtual Machine. Smart contracts are self-executing programs written in Solidity that automatically carry out agreements when conditions are met, eliminating intermediaries like banks or brokers.   Validators stake ETH as collateral to propose and validate blocks, earning rewards for honest participation while facing penalties for malicious behavior. The EIP-1559 upgrade introduced a dynamic base fee mechanism that burns ETH with each transaction, creating deflationary pressure during high network activity when more ETH is burned than issued to validators.  Vitalik Buterin proposed Ethereum in 2013, but seven co-founders helped build it, including Gavin Wood who created Solidity and the EVM technical specification, and Joseph Lubin who founded ConsenSys. The project launched in July 2015 after raising over $18 million through crowdfunding, quickly becoming the largest blockchain developer community. Major milestones include the 2020 Beacon Chain launch, the 2021 London hard fork implementing fee burning, and the 2022 Merge to Proof of Stake.   Ether (ETH) serves multiple functions: paying transaction fees (gas), staking to secure the network and earn 3-5% annual yields, serving as collateral in DeFi protocols, and purchasing NFTs and digital assets. The asset is increasingly adopted by traditional institutions, with publicly traded companies adding ETH to corporate treasuries to generate staking yields while maintaining blockchain exposure, and in 2024, the SEC approved spot Ethereum ETFs, allowing traditional investors to gain exposure through conventional brokerage accounts.  Ethereum's roadmap focuses on dramatically increasing transaction capacity to over 100,000 per second, reducing confirmation times, and enhancing decentralization while maintaining security against future threats like quantum computing.

Ethereum

Ethereum is facing downward pressure amid community anxiety over stagnant price action, macro volatility linked to geopolitical tensions, and ongoing debate regarding the impact of institutional manipulation. Traders remain divided between those viewing the current consolidation as a deep-value buying opportunity and those frustrated by the asset's failure to mirror the gains seen in broader equity markets.

Invesco Exchange-Traded Fund Trust - Invesco S&P 500 Equal Weight ETF

Invesco S&P 500 Equal Weight ETF

Investors are closely watching the performance gap between market-cap weighted indices like the S&P 500 and the Invesco S&P 500 Equal Weight ETF (RSP), as the latter serves as a key barometer for market breadth. The community is actively debating whether recent volatility reflects a healthy rotation out of concentrated mega-cap tech into broader market participation, or if it indicates early signs of fragility beneath the index-level highs.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is facing significant downward pressure as market participants debate its role as a hedge against inflation and war, with many expressing frustration over its lack of correlation to the broader equities market rally. The community is actively discussing the impact of potential geopolitical escalation, ETF outflows, and the perceived influence of institutional selling, leading to a polarized environment where bears watch for a breakdown of support levels while bulls look for accumulation opportunities.

Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in San Diego, CA.

Kura Oncology Inc

Kura Oncology is currently trending as investors focus on the upcoming PDUFA date for ziftomenib, with the community highlighting its potential for a best-in-class safety profile and once-daily dosing as competitive advantages against existing market options. Market participants are also tracking pipeline progress in its farnesyl transferase inhibitor programs while monitoring institutional activity for potential momentum shifts.

Best Buy Co., Inc. engages in the provision of consumer technology products and services. It operates through two business segments: Domestic and International. The Domestic segment includes operations in all states and territories of the U.S., operating under various brand names, including Best Buy, Best Buy Mobile, Geek Squad, Magnolia Audio Video, and Pacific Sales. The International segment consists of operations in Canada. It also markets its products under the brand names: Best Buy, bestbuy.com, Best Buy Express, Lively, Geek Squad, Magnolia and Pacific Kitchen and Home. The company was founded by Richard M. Schulze in 1966 and is headquartered in Richfield, MN.

Best Buy Co. Inc.

Best Buy is trending as investors weigh strong fourth-quarter profit beats against persistent macroeconomic pressures and aggressive tariff-related concerns. The community is actively debating the company's long-term retail viability, with significant discourse surrounding potential store closures, leadership execution, and speculation about future acquisition interest.

Bright Minds Biosciences, Inc. is a biotechnology company, which engages in the development of therapeutics. The company was founded by Ian B. McDonald and Alan P. Kozikowski on May 31, 2019 and is headquartered in Chicago, IL.

Bright Minds Biosciences Inc

Bright Minds Biosciences is trending as investors draw comparisons to historic biotech breakouts, fueled by speculation surrounding its Phase 2 pipeline progress and the potential for a major strategic partnership or buyout. Community sentiment remains highly active with many hopeful for a low-float squeeze, though discussions frequently debate the risks of small-cap volatility and the company's long-term operational execution.

Procure ETF Trust II - Procure Space ETF

The Procure Space ETF is attracting significant investor attention as the space sector gains momentum from major government contracts and the anticipation surrounding SpaceX's potential IPO. The community remains focused on the ETF's exposure to pure-play aerospace companies, debating the long-term potential of the space economy compared to traditional defense contractors.

Solana is a high-performance Layer 1 blockchain designed for mass adoption by providing a fast, secure, and low-cost environment for decentralized applications. It distinguishes itself by scaling globally without the use of complex sharding or multiple layers, instead maintaining a single, unified ledger to avoid liquidity fragmentation. This architecture allows it to process thousands of transactions per second with sub-second finality, often at a cost of less than a penny per transaction.  The network operates on a unique hybrid model that combines Proof of Stake with an innovation called Proof of History, which functions as a decentralized clock to timestamp transactions. This system reduces the need for constant node communication, allowing the Sealevel engine to run non-conflicting smart contracts in parallel across multiple CPU cores. Further efficiency is gained through the Gulf Stream protocol, which reduces confirmation times by forwarding transactions to validators before the current block is finished.  Founded in 2017 by Anatoly Yakovenko, Solana is now supported by the Switzerland-based Solana Foundation and significant institutional investors like Andreessen Horowitz and Polychain Capital. The platform’s native token, SOL, serves as the primary currency for paying transaction fees, participating in network governance, and securing the system through staking.   Solana has also seen significant institutional adoption ranging from spot Solana ETFs to major partnerships including Visa's 2025 launch of USDC settlement on the network and the tokenization of public equity by firms like Galaxy Digital.

Solana

Solana is currently a major focus for investors navigating market volatility, with community sentiment driven by debates over its long-term network throughput compared to other chains and interest in ongoing meme coin activity. Discussions remain heavily polarized between long-term holders advocating for staking strategies and bearish traders reacting to broader crypto market pressure and regulatory headlines.

statis crypto Watchlist

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Tarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Beats Revenue Estimates

Tarsus Pharmaceuticals (TARS) delivered earnings and revenue surprises of +64.91% and +9.64%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

HC Wainwright Issues Pessimistic Outlook for TARS Earnings

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) - Equities researchers at HC Wainwright decreased their Q1 2026 earnings per share estimates for shares of Tarsus Pharmaceuticals in a research note issued to investors on Monday, May 4th. HC Wainwright analyst M. Caufield now forecasts that t...

Tarsus Pharmaceuticals (NASDAQ:TARS) Earns Buy Rating from HC Wainwright

HC Wainwright reiterated a "buy" rating and set a $88.00 price objective on shares of Tarsus Pharmaceuticals in a research note on Monday...

D.A. Davidson & CO. Takes $1.49 Million Position in Tarsus Pharmaceuticals, Inc. $TARS

D.A. Davidson & CO. purchased a new stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange...

Amgen (AMGN) Q1 Earnings and Revenues Beat Estimates

Amgen (AMGN) delivered earnings and revenue surprises of +8.87% and +1.71%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Jennison Associates LLC Sells 374,511 Shares of Tarsus Pharmaceuticals, Inc. $TARS

Jennison Associates LLC cut its stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 14.4% in the 4th quarter, according to its most recent filing with the Securities and Exchange...

Tarsus Pharmaceuticals is Now Oversold (TARS)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a...

Universal Beteiligungs und Servicegesellschaft mbH Increases Holdings in Tarsus Pharmaceuticals, Inc. $TARS

Universal Beteiligungs und Servicegesellschaft mbH grew its position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 19.9% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 109,857 shares of the...

Calamos Advisors LLC Makes New $2.82 Million Investment in Tarsus Pharmaceuticals, Inc. $TARS

Calamos Advisors LLC purchased a new position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) during the fourth quarter, according to its most recent 13F filing with the...

Tarsus Pharmaceuticals (NASDAQ:TARS) Now Covered by Analysts at Oppenheimer

Oppenheimer began coverage on Tarsus Pharmaceuticals in a report on Friday. They set an "outperform" rating and a $98.00 price target for the company...

Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of therapeutic candidates. Its product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of blepharitis caused by the infestation of Demodex mites, which is referred to as Demodex blepharitis. It is also developing TP-04 for the potential treatment of Ocular Rosacea and TP-05 as an oral tablet for the potential prevention of Lyme disease. The company was founded by Bobak Azamian and D. Michael Ackermann in 2017 and is headquartered in Irvine, CA.

TARS
Tarsus Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Compact View

Latest TARS News

TARSTarsus Pharmaceuticals Inc